Drug intelligence / Profile preview

betamethasone + oxitropium bromide + salbutamol

Development stage: Preclinical
Lead developer: Merck
Modality: Small Molecules
Administration: Inhalation

Overview

A combination medication containing betamethasone (a corticosteroid), oxitropium bromide (an anticholinergic bronchodilator), and salbutamol (a short-acting beta-2 adrenergic agonist). This combination likely provides complementary mechanisms of action for treating respiratory conditions such as asthma and COPD, with betamethasone providing anti-inflammatory effects, oxitropium bromide preventing bronchoconstriction through muscarinic receptor blockade, and salbutamol causing bronchodilation through beta-2 receptor stimulation.

Targets

mAChR (Muscarinic acetylcholine receptors)GR (Glucocorticoid receptor)ADRB2 (β2)

Beyond the preview

Go deeper on betamethasone + oxitropium bromide + salbutamol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on betamethasone + oxitropium bromide + salbutamol.

Explore the full profile